文献速递前列腺癌

前列腺切除术后复发前列腺癌:PSA<0.5 ng/ml早期挽救放疗及SRT后PSA最低值的影响

Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-11-28

该多中心回顾性研究纳入301例根治性前列腺切除术后复发、未接受过雄激素剥夺治疗且PSA<0.5 ng/ml时接受挽救放疗的患者,中位随访5.9年。结果显示SRT前PSA<0.2 ng/ml与SRT后PSA不可测(<0.1 ng/ml)显著相关,并带来更优的无进展生存和总生存。

要点

  • SRT前PSA<0.2 ng/ml者仅9%未能达到SRT后PSA不可测。
  • SRT后PSA最低值≥0.1 ng/ml在多变量分析中主导结局(HR=9.00)。
  • SRT前PSA<0.2 ng/ml者5.9年总生存98%,高于较高PSA者的91%(Logrank p=0.004)。

核心结论

  • PSA<0.2 ng/ml时行SRT与SRT后PSA不可测(<0.1 ng/ml)显著相关,并随后与改善的无进展生存相关。
  • 鉴于总体结局良好,这些患者是否需要额外雄激素剥夺治疗尚需进一步研究。

研究设计与样本

  • 1998至2013年间两所大学医院的301例根治性前列腺切除术后复发患者,在PSA<0.5 ng/ml(中位0.192 ng/ml,IQR 0.110-0.300)时接受SRT。
  • 排除既往接受雄激素剥夺治疗者;全部接受3D适形放疗或IMRT(n=59),中位剂量66.6 Gy;中位随访5.9年;终点为进展和总生存。

主要发现

  • SRT后252例患者重新达到PSA不可测。
  • 单变量分析中,根治前PSA≥10 ng/ml、pT3-4、Gleason评分7-10或8-10、手术切缘阴性、根治后PSA≥0.1 ng/ml、SRT前PSA≥0.2 ng/ml及SRT后PSA最低值≥0.1 ng/ml与SRT后进展不利相关。
  • 多变量Cox模型中,pT3-4、Gleason评分7-10、切缘阴性和SRT前PSA≥0.2 ng/ml为显著危险因素。
  • 若将SRT后PSA加入分析,其主导结局(HR=9.00)。
  • SRT前PSA<0.2 ng/ml者中仅9%未能达到PSA不可测;这些患者5.9年总生存98%,而SRT前PSA较高者为91%(Logrank p=0.004)。

关键数值与推荐

  • 欧洲指南(EAU)推荐在PSA<0.5 ng/ml时行SRT。
  • 本研究支持在PSA<0.2 ng/ml时行SRT与SRT后PSA不可测(<0.1 ng/ml)显著相关。

临床怎么用

  • 对于根治性前列腺切除术后生化复发患者,可考虑在PSA<0.2 ng/ml时尽早启动挽救放疗以争取SRT后PSA不可测。
  • SRT后应监测PSA最低值,若≥0.1 ng/ml提示进展风险显著升高。
  • 对PSA<0.2 ng/ml即接受SRT且结局良好者,是否联合雄激素剥夺治疗需个体化并进一步研究。

局限性

  • 回顾性研究设计。
  • 仅纳入两所大学医院的患者。
  • 排除既往接受雄激素剥夺治疗者,可能限制外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) offers a second chance of cure. European guidelines (EAU) recommend SRT at a PSA < 0.5 ng/ml. We analyze the efficacy of SRT given according to this recommendation and investigate the predictive power of the post-SRT PSA nadir. METHODS: Between 1998 and 2013, 301 patients of two university hospitals received SRT at a PSA < 0.5 ng/ml (median 0.192 ng/ml, IQR 0.110-0.300). Patients, who previously received androgen deprivation therapy, were excluded. All patients had 3D-conformal RT or intensity-modulated radiotherapy (IMRT, n = 59) (median 66.6 Gy). The median follow-up was 5.9 years. Progression and overall survival were the endpoints. RESULTS: After SRT, 252 patients re-achieved an undetectable PSA. In univariate analysis, pre-RP PSA ≥ 10 ng/ml, pT3-4, Gleason score (GS) 7-10 or 8-10, negative surgical margins, post-RP PSA ≥ 0.1 ng/ml, pre-SRT PSA ≥ 0.2 ng/ml and post-SRT PSA nadir ≥ 0.1 ng/ml correlated unfavorably with post-SRT progression. In a multivariable Cox model, pT3-4, GS 7-10, negative margins and a pre-SRT PSA ≥ 0.2 ng/ml were significant risk factors. If the post-SRT PSA was added to the analysis, it dominated the outcome (HR = 9.00). Of the patients with a pre-SRT PSA < 0.2 ng/ml, only 9% failed re-achieving an undetectable PSA. Overall survival in these patients was 98% after 5.9 years compared to 91% in patients with higher pre-SRT PSA (Logrank p = 0.004). CONCLUSIONS: SRT at a PSA < 0.2 ng/ml correlates significantly with achieving a post-SRT undetectable PSA (<0.1 ng/ml) and subsequently with improved freedom from progression. Given these overall favorable outcomes, whether additional androgen deprivation therapy is required for these men requires further study.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bottke D, Bartkowiak D, Siegmann A, et al. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30487644. doi:10.1038/s41391-018-0112-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。